Cannabinoid Researcher Granted Patent for Its Women’s Viagra

Vella Bioscience of New York, the maker of Women’s Pleasure Serum, a cannabinoid-based wellness product to treat antidepressant-induced female sexual dysfunction, announced this week that the U.S. Patent and Trademark Office has granted the brand’s its first patent.

The company’s first, the patent covers formulas and processes behind the use of hemp and/or CBD — as well as combinations with other active topical agents — for treating female sexual dysfunction from the use of selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs) and other common antidepressants. Millions of women taking antidepressants discontinue treatment due to sexual side-effects.

The patent grant, which also covers the company’s proprietary encapsulated liposomal on-demand CBD, will lay the foundation for a upcoming spin-out pharmaceutical company. Vella will form a wholly new pharmaceutical entity to now pursue an FDA-approved treatment.

“SSRI-induced sexual dysfunction is common in women and to date there is no effective treatment. Our newly issued patent covering our novel, topical approach to this disorder will be the impetus for the formation of a new company focused on this huge unmet need in women’s health, says Dr. Harin Padma-Nathan, MD, FRCS(C). Dr Padma-Nathan has been the lead principal investigator for over 110 clinical trials, including Viagra.

To learn more about Vella Bioscience visit http://www.vellabio.com.